Literature DB >> 16399492

Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients.

Giuseppe Mulè1, Santina Cottone, Rosalia Mongiovì, Paola Cusimano, Giovanni Mezzatesta, Giovanna Seddio, Vito Volpe, Emilio Nardi, Giuseppe Andronico, Giuseppe Piazza, Giovanni Cerasola.   

Abstract

BACKGROUND AND AIM: Metabolic syndrome (MS) carries an increased risk for cardiovascular events and there is a growing awareness that large artery stiffening is a powerful predictor of cardiovascular morbidity and mortality. Little is known about the relationship of MS with aortic stiffness. The aim of our study was to analyze, in patients with essential hypertension, the influence of MS, defined according to the criteria proposed by the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP-ATP III), on carotid-femoral pulse wave velocity (PWV), a measure of aortic stiffness.
METHODS: Ninety-three untreated essential hypertensives, aged between 23 and 61 years, without diabetes mellitus, were studied. All subjects underwent routine blood chemistry, oral glucose tolerance test with glucose and insulin determinations, albumin excretion rate (AER) measurement, 24-h ambulatory blood pressure monitoring, and measurement of carotid-femoral PWV, by means of a computerized method.
RESULTS: Patients with MS (n = 28) showed higher age-adjusted carotid-femoral PWV (10.1 +/- 1.4 vs 9.3 +/- 1.4 m/s; p = 0.01) when compared to subjects without MS. This difference held after controlling for gender and for 24-h mean blood pressure (MBP) (p = 0.02) and lost its statistical significance after further adjustment for AER. In a multiple regression model, excluding the individual components of MS, in which metabolic syndrome was added along with age, gender, smoking habit, LDL cholesterol, HOMA index, 24-h MBP and 24-h heart rate, MS remained independently associated with carotid-femoral PWV (beta = 0.29; p = 0.002). The statistical significance of this association disappeared after the inclusion into this model of AER.
CONCLUSIONS: Metabolic syndrome is associated with an increased aortic stiffness. Main explanatory factors of this association are age, systolic blood pressure and albumin excretion rate.

Entities:  

Mesh:

Year:  2005        PMID: 16399492     DOI: 10.1016/j.numecd.2005.03.005

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  11 in total

Review 1.  Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease.

Authors:  C D A Stehouwer; R M A Henry; I Ferreira
Journal:  Diabetologia       Date:  2008-02-01       Impact factor: 10.122

2.  Partial normalization of components of metabolic syndrome does not influence prevalent echocardiographic abnormalities: the HyperGEN study.

Authors:  G de Simone; D K Arnett; M Chinali; M De Marco; D C Rao; A T Kraja; S C Hunt; R B Devereux
Journal:  Nutr Metab Cardiovasc Dis       Date:  2011-05-12       Impact factor: 4.222

Review 3.  New insights into arterial stiffening: does sex matter?

Authors:  Benard O Ogola; Margaret A Zimmerman; Gabrielle L Clark; Caleb M Abshire; Kaylee M Gentry; Kristin S Miller; Sarah H Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-07-20       Impact factor: 4.733

Review 4.  Metabolic syndrome in hypertensive patients: An unholy alliance.

Authors:  Giuseppe Mulè; Ilenia Calcaterra; Emilio Nardi; Giovanni Cerasola; Santina Cottone
Journal:  World J Cardiol       Date:  2014-09-26

5.  Anti-inflammatory effect of amlodipine plus atorvastatin treatment on carotid atherosclerosis in zucker metabolic syndrome rats.

Authors:  Xuemei Zhang; Fengfeng Tian; Hiromi Kawai; Tomoko Kurata; Shoko Deguchi; Kentaro Deguchi; Jingwei Shang; Ning Liu; Wentao Liu; Yoshio Ikeda; Tohru Matsuura; Tatsushi Kamiya; Koji Abe
Journal:  Transl Stroke Res       Date:  2012-07-21       Impact factor: 6.829

6.  Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study.

Authors:  G de Simone; R B Devereux; M Chinali; M J Roman; E T Lee; H E Resnick; B V Howard
Journal:  Nutr Metab Cardiovasc Dis       Date:  2008-07-31       Impact factor: 4.222

7.  Retinal blood flow velocity in metabolic syndrome.

Authors:  Shay Gutfreund; Elena Izkhakov; Russell Pokroy; Marianna Yaron; Hanny Yeshua; Zvia Burgansky-Eliash; Adiel Barak; Ardon Rubinstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-05       Impact factor: 3.117

Review 8.  The metabolic syndrome and its relationship to hypertensive target organ damage.

Authors:  Giuseppe Mulè; Giovanni Cerasola
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-03       Impact factor: 3.738

9.  PPAR-gamma in the Cardiovascular System.

Authors:  Sheng Zhong Duan; Christine Y Ivashchenko; Michael G Usher; Richard M Mortensen
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

10.  Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome.

Authors:  Giovanni Cioffi; Ombretta Viapiana; Luigi Tarantini; Giovanni Orsolini; Luca Idolazzi; Federica Ognibeni Sonographer; Andrea Dalbeni; Davide Gatti; Angelo Fassio; Maurizio Rossini; Alessandro Giollo
Journal:  Intern Emerg Med       Date:  2020-10-20       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.